SCHEMBL30044228

SCHEMBL30044228

O=Cc1ccc2c(c1)C(=O)N([C@@H]1CCC(=O)NC1=O)C2=O

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 18/20 0.68
▸ DDB1 Q16531 12/20 0.68
▸ IKZF3 Q9UKT9 2/20 0.68
▸ ALDH1A1 P00352 1/20 0.68
▸ CHRM2 P08172 1/20 0.68
▸ OPRM1 P35372 1/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ TSHR P16473 1/20 0.68
▸ TDP1 Q9NUW8 1/20 0.68
▸ IKZF1 Q13422 2/20 0.55
▸ IKZF2 Q9UKS7 1/20 0.55
▸ TNF P01375 1/20 0.53
▸ IL1B P01584 1/20 0.53
▸ TBXA2R P21731 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22358875 1.00 CRBN (0.68) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29614513 0.88 CRBN (0.67) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24421178 0.88 CRBN (0.67) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24501019 0.88 CRBN (0.67) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL27178919 0.86 CRBN (0.64) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30738830 0.83 CRBN (0.63) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21554544 0.83 CRBN (0.63) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL27178849 0.83 CRBN (0.63) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31274384 0.83 CRBN (0.63) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL27178856 0.83 CRBN (0.63) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4107158-A1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF Nurix Therapeutics, Inc. (US) 2022-12-28 — — EP disclosed
CN-115335381-A Bifunctional degradants of interleukin-1 receptor-associated kinase and therapeutic uses thereof 新锐思生物制药股份有限公司 2022-11-11 — — CN disclosed
Send feedback